Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Also we have no institutional support because we are on the otc market.
Also it's important to remember that our financing is adding to the selling pressure. Not that it's bad but it definitely can put downward pressure on the pps
Our market(otc) has only retail, so I am not sure how reliable it is.
Arena pharma was way down going into their recent phase 2 results so I am not sure how much "the market" really knows.
If you don't feel it's not having the intended impact then why are you spending so much time here?
Thanks for the post. Again very interesting.
This very interesting! Wow! We were told trial results always leak! ;)
Lmao! We showed visual conclusive evidence but yes it was a poc trial. It showed potential B partners the anti-inflammatory properties and the potential for a huge indication.
What's good about someone having UP?
How does one define a trial failure exactly? The primary end points are agreeded to by the company and the fda. That's why they meet with the fda otherwise it would just be a fishing expedition and potentially endanger patients.
So your saying the fda allows frivolous trials to proceed even when they don't meet their end points that they agreed to? I thought you said they were only interested in safety? That doesn't sound safe to me and our trial doubles the dose!
If the fda doesn't care about trials why did they make us run a phase 1 trial? Are you saying that the fda doesn't care about the agreed upon end points? I agree companies can run many trials for different drugs as a scam but not the same drug.
So what you're saying is if a phase 2A trial fails they can move on to a phase 2B trial and the FDA doesn't care. That's not how I understand it. If the company failed a phase 2A trial and wanted to redo the trial they could but they can't move on to a phase 2B trial.
As usual you didn't address his point! The fda wouldn't allow trial if the 1st trial failed(which is what you said).
There are way to many social media support groups that you can only search by being a member to discount his story. Also his story was way to detailed for him to make up(my opinion) . Of course I know this is an anonymous message board but I didn't see any outrageous posts in his past posts.
All of the social media sites have many many support sites in addition to the big online support sites.
Omg! Wow! Just how do you know this? What's your source? Are you going to Beverly to check on the staff? It sounds a lot like Mako!
This kind of PR really pissed off the gang here. It completely refutes their story.
TIAB is a fraud. He is just working the board like all the rest of them. Will P workout I have know idea.
I said this yesterday. Ipix is an easy Mark for all you traders and shorts. 1. Constant supply of shares from financing 2. No institutional support because of our market 3. Time between major news events.
The good news is the science is moving forward.
Just be honest and say you want to drive the price down!
Sixty cents, it's been pointed out again again that biotech investing takes patients, lots of patients. The P trial like most trials took longer the anticipated. We will see results soon enough!
But something is different now. We have never gone this long without a PR or update.
I think ipix has been an easy Mark for those who want to trade or short. The company has no institutional support, the financing creates a constant supply of shares and the trials take a lot of time. None of this takes away from the science and the potential for success.
He is probably staying on because he has a good feeling the trial will be a success and there are B deals ready to finish!
Dr B's resume shows a pattern of new employment every 2 years... If P fails, I'll bet he departs shortly after. LMAO! Now I know you spreading BS! First of all he has a very impressive resume and 2nd it looks just like everyone else's resume in the biotech industry.
Do you? Unlike some I have never said I knew the outcome. How could someone know the outcome? Please tell me? I guess if some one is an arrogant sob maybe they think they know the answer, right?
I do know that we'll get it when it's ready Agreed!
No thanks! You were the one to question the medicinal chemistry work of the company regarding P but not B. I have no idea how the P trial is going to go. Maybe you weren't around when ipix rescued B with the 2B trial but I am pretty sure they used a little medicinal chemistry.
Since you brought up wording and the email...the quote was "We projected to have the data this quarter" I read that as "we planned" meaning that was the plan but we don't have the info yet.
Why would you invest in a company that doesn't understand medicinal chemistry?
Why would you think ipix would have any chance of developing a acne drug when they don't understand medicinal chemistry?
What an amazing concept! Maybe you should go into the pharma business as a consultant and help out companies like ipix because they haven't run as many trials as you have I am sure!
It's very evident you don't nor ever have run a trial.
I think biodoc has way to much class to respond. Lol!
I think it's interesting listening to the debate about the P2b study and compare it to the B ABBSSI study discussions. It definitely wasn't a fore gone conclusion that the study was going to be a success. The B2a had many issues and many question marks. At the time many of the "scientific" posters only gave it a 60% chance at best of success. The company has done a great job working with limited resources and moving the trials forward.
Thanks PP! Much appreciated.
He said "ready" dude not started! Get a grip.
So your saying Leo is lying in a PR and opening himself up to legal issues. Lol!
I am not sure our market(otc) with only retail investors is a very good representation of true investor sentiment.